LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code is needed.
Therapeutic Strategies to Overcome ALK Resistance in Cancer
- 1st Edition, Volume 13 - January 5, 2021
- Editor: Luc Friboulet
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 2 1 7 7 4 - 0
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 1 7 7 9 - 5
Therapeutic Strategies to Overcome ALK Resistance in Cancer, Volume 13, presents current strategies to improve and prolong clinical benefit in ALK driven cancers. Most patients… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteTherapeutic Strategies to Overcome ALK Resistance in Cancer, Volume 13, presents current strategies to improve and prolong clinical benefit in ALK driven cancers. Most patients with ALK-driven cancer are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops. This book discusses topics such as structure and function of ALK, ALK rearranged lung cancer, resistance mechanisms to ALK TKI tumors, and novel therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL. Additionally, it encompasses information on drug combinations to enhance ALK TKI anti-tumor efficacy in neuroblastoma and future perspectives in the field.
This book is a valuable resource for cancer researchers, clinicians and several members of biomedical field who need to understand more about how to fight ALK resistance in cancer treatment.
- Explains the biology of ALK RTK, focusing on its tissue expression, structure and functionality
- Presents an overview of current treatments and the benefits of ALK TKI in lung and other cancer types, such as ALCL, neuroblastoma and inflammatory myofibroblastic tumor
- Encompasses information on systemic treatments other than TKI, including chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC
1. Structure and function of ALK2. ALK rearranged lung cancer: Treatment and outcome3. Systemic treatments other than TKI: reflections on chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC4. Management of ALK positive patients with tumors other than lung cancer (ALCL, neuroblastoma, Inflammatory Myofibroblastic Tumor)5. Resistance mechanisms to ALK TKIs in lung cancer: from single to compound mutations, from tissue to liquid biopsy6. Resistance mechanisms to ALK TKI in tumors other than lung cancer7. Therapeutic strategies to overcome ALK resistance in lung cancer8. Novel Therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL: use of ACD9. Drug combinations to enhance ALK TKI anti-tumor efficacy in Neuroblastoma10. State of the art and future perspectives
- No. of pages: 216
- Language: English
- Edition: 1
- Volume: 13
- Published: January 5, 2021
- Imprint: Academic Press
- Hardback ISBN: 9780128217740
- eBook ISBN: 9780128217795
LF
Luc Friboulet
Luc Friboulet, PhD, is ERC Principal Investigator and INSERM team leader at Gustave Roussy cancer campus. He studies the tumor adaptation to kinase inhibitors. Linked to a clinical trial named MATCH-R allowing collection of repeated biopsies in patients treated with ALK, ROS1, RET, EGFR, BRAF, FGFR inhibitors Dr. Friboulet characterizes the resistance mechanisms and establishes new laboratory models.
Affiliations and expertise
ERC Principal Investigator and INSERM Team Leader, Gustave Roussy Cancer Campu, FranceRead Therapeutic Strategies to Overcome ALK Resistance in Cancer on ScienceDirect